{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T07:16:19Z","timestamp":1778915779739,"version":"3.51.4"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T00:00:00Z","timestamp":1274313600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0010750","type":"journal-article","created":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T20:20:05Z","timestamp":1274386805000},"page":"e10750","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["Comparative Therapeutic Effects of Velaglucerase Alfa and Imiglucerase in a Gaucher Disease Mouse Model"],"prefix":"10.1371","volume":"5","author":[{"given":"You-Hai","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2010,5,20]]},"reference":[{"key":"ref1","first-page":"3635","article-title":"Gaucher Disease.","author":"E Beutler","year":"2001"},{"key":"ref2","first-page":"177","article-title":"The pathology of Gaucher disease.","volume":"95","author":"RE Lee","year":"1982","journal-title":"Prog Clin Biol Res"},{"key":"ref3","first-page":"1045","article-title":"From Cytases to Lysosomes.","volume":"23","author":"C Deduve","year":"1964","journal-title":"Fed Proc"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts.","volume":"162","author":"JC Fratantoni","year":"1968","journal-title":"Science"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher's disease.","volume":"324","author":"NW Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.","volume":"122","author":"GA Grabowski","year":"1995","journal-title":"Ann Intern Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(95)91038-7","article-title":"Replacement therapy with imiglucerase for type 1 Gaucher's disease.","volume":"345","author":"A Zimran","year":"1995","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0002-9343(02)01150-6","article-title":"Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry.","volume":"113","author":"NJ Weinreb","year":"2002","journal-title":"Am J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood.V93.9.2807","article-title":"A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease.","volume":"93","author":"B Friedman","year":"1999","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood.V82.2.408.408","article-title":"Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months.","volume":"82","author":"GM Pastores","year":"1993","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1542\/peds.96.4.629","article-title":"Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.","volume":"96","author":"DI Rosenthal","year":"1995","journal-title":"Pediatrics"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","article-title":"Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy.","volume":"104","author":"RJ Wenstrup","year":"2004","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.","volume":"71","author":"J Charrow","year":"2007","journal-title":"Clin Genet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0022-3476(96)70203-2","article-title":"Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.","volume":"129","author":"P Kaplan","year":"1996","journal-title":"J Pediatr"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1203\/00006450-199205000-00018","article-title":"Enzyme augmentation in moderate to life-threatening Gaucher disease.","volume":"31","author":"S Fallet","year":"1992","journal-title":"Pediatr Res"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V78.5.1183.1183","article-title":"Enzyme replacement therapy for Gaucher disease.","volume":"78","author":"E Beutler","year":"1991","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1515\/BC.2008.163","article-title":"Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy.","volume":"389","author":"Y Kacher","year":"2008","journal-title":"Biol Chem"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","article-title":"Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1.","volume":"11","author":"GA Grabowski","year":"2009","journal-title":"Genet Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpeds.2003.10.067","article-title":"Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations.","volume":"144","author":"J Charrow","year":"2004","journal-title":"J Pediatr"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1172\/JCI116409","article-title":"Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages.","volume":"91","author":"Y Sato","year":"1993","journal-title":"J Clin Invest"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0304-4165(81)90474-8","article-title":"Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation.","volume":"673","author":"FS Furbish","year":"1981","journal-title":"Biochim Biophys Acta"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1432-1033.1996.00344.x","article-title":"Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells.","volume":"237","author":"MK Bijsterbosch","year":"1996","journal-title":"Eur J Biochem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1203\/00006450-199602000-00021","article-title":"Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues.","volume":"39","author":"YH Xu","year":"1996","journal-title":"Pediatr Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/0046-8177(95)90097-7","article-title":"Pathological findings in Gaucher disease type 2 patients following enzyme therapy.","volume":"26","author":"KE Bove","year":"1995","journal-title":"Hum Pathol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease.","volume":"41","author":"GM Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"10551","DOI":"10.1016\/S0021-9258(18)67420-4","article-title":"Lec1A Chinese hamster ovary cell mutants appear to arise from a structural alteration in N-acetylglucosaminyltransferase I.","volume":"261","author":"W Chaney","year":"1986","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"15599","DOI":"10.1016\/S0021-9258(18)55439-9","article-title":"Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I.","volume":"265","author":"AD Elbein","year":"1990","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/S0021-9258(17)42166-1","article-title":"Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression.","volume":"269","author":"ME Grace","year":"1994","journal-title":"J Biol Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1074\/jbc.M511110200","article-title":"Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations.","volume":"281","author":"B Liou","year":"2006","journal-title":"J Biol Chem"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.","volume":"9","author":"DA Brooks","year":"2003","journal-title":"Trends Mol Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","article-title":"Enzyme reconstitution\/replacement therapy for lysosomal storage diseases.","volume":"19","author":"TA Burrow","year":"2007","journal-title":"Curr Opin Pediatr"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration.","volume":"93","author":"M Rosenberg","year":"1999","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.","volume":"163","author":"YH Xu","year":"2003","journal-title":"Am J Pathol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"29052","DOI":"10.1074\/jbc.M705005200","article-title":"Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease.","volume":"282","author":"B Brumshtein","year":"2007","journal-title":"J Biol Chem"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nchembio850","article-title":"Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease.","volume":"3","author":"RL Lieberman","year":"2007","journal-title":"Nat Chem Biol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"23815","DOI":"10.1074\/jbc.M502799200","article-title":"X-ray structure of human acid-beta-glucosidase covalently bound to conduritol-B-epoxide. Implications for Gaucher disease.","volume":"280","author":"L Premkumar","year":"2005","journal-title":"J Biol Chem"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0022-1759(84)90046-2","article-title":"Determination of blood volume in the mouse with 51chromium-labelled erythrocytes.","volume":"73","author":"W Sluiter","year":"1984","journal-title":"J Immunol Methods"},{"key":"ref38","first-page":"141","article-title":"Monocyte\/macrophage-reactive monoclonal antibody Ki-M6 recognizes an intracytoplasmic antigen.","volume":"125","author":"MR Parwaresch","year":"1986","journal-title":"Am J Pathol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0021-9258(17)42428-8","article-title":"Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase.","volume":"261","author":"S Tsuji","year":"1986","journal-title":"J Biol Chem"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"16746","DOI":"10.1016\/S0021-9258(19)89454-1","article-title":"Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase.","volume":"269","author":"X Qi","year":"1994","journal-title":"J Biol Chem"},{"key":"ref41","first-page":"15","article-title":"Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting.","volume":"40","author":"D Fabbro","year":"1987","journal-title":"Am J Hum Genet"},{"key":"ref42","first-page":"741","article-title":"Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts.","volume":"44","author":"JE Bergmann","year":"1989","journal-title":"Am J Hum Genet"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-{beta}-glucosidase: Crystal structure, glycan composition, and internalization into macrophages.","volume":"20","author":"B Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/glycob\/cwm008","article-title":"Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease.","volume":"17","author":"SM Van Patten","year":"2007","journal-title":"Glycobiology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1086\/498652","article-title":"The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy.","volume":"77","author":"H Du","year":"2005","journal-title":"Am J Hum Genet"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1517\/14656560903270520","article-title":"Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships.","volume":"10","author":"CE Hollak","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2007.04.001","article-title":"A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.","volume":"91","author":"KA McEachern","year":"2007","journal-title":"Mol Genet Metab"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.83.6.1660","article-title":"Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site.","volume":"83","author":"T Dinur","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1194\/jlr.M500202-JLR200","article-title":"Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants.","volume":"46","author":"Y Sun","year":"2005","journal-title":"J Lipid Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.4049\/jimmunol.165.11.6429","article-title":"The role of macrophage inflammatory protein-1 alpha\/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection.","volume":"165","author":"MA Olszewski","year":"2000","journal-title":"J Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0010750","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T01:12:03Z","timestamp":1740100323000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0010750"}},"subtitle":[],"editor":[{"given":"Raphael","family":"Schiffmann","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,5,20]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2010,5,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0010750","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,20]]}}}